Stockscreener 앱 받기
5.48
0.54%
-0.03
시간 외 거래:
5.47
-0.01
-0.18%
전일 마감가:
$5.51
열려 있는:
$5.48
하루 거래량:
636.02K
Relative Volume:
0.51
시가총액:
$1.23B
수익:
$596.48M
순이익/손실:
$123.72M
주가수익비율:
9.9927
EPS:
0.5484
순현금흐름:
$106.59M
1주 성능:
+0.74%
1개월 성능:
+1.29%
6개월 성능:
+50.14%
1년 성능:
+68.62%
1일 변동 폭
$5.48
$5.535
1주일 범위
$5.41
$5.54
52주 변동 폭
$2.37
$5.72
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.48 | 1.24B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
CureVac Reports Financial Losses in Mid-2025 - MSN
CureVac N.V. Stages Intraday Comeback — Trend Change2025 Institutional Moves & High Accuracy Trade Signal Alerts - sundaytimes.kr
CureVac's Q2 Pre-Tax Loss Narrows, Revenue Falls - MarketScreener
Earnings Flash (CVAC) CureVac Posts Q2 Revenue 1.2M Euros, vs. FactSet Est of 3.3M Euros - MarketScreener
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates | CVAC Stock News - GuruFocus
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - ACCESS Newswire
$740M Patent Settlement: CureVac Resolves Pfizer Dispute and Agrees to BioNTech Acquisition Deal - Stock Titan
How does CureVac N.V. compare to its peersExit Point & Risk Managed Investment Strategies - thegnnews.com
Is CureVac N.V. part of any ETF2025 Short Interest & AI Driven Stock Price Forecasts - sundaytimes.kr
Is There Enough Volume to Lift CureVac N.V.Weekly Market Report & Free Long-Term Investment Growth Plans - newsyoung.net
CureVac NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Key resistance and support levels for CureVac N.V.High Return Strategy with Low Risk - Newser
Analyzing CureVac (NASDAQ:CVAC) & ARAVIVE (NASDAQ:ARAV) - Defense World
Can CureVac N.V. keep up with sector leadersSmart Money ROI Picks - sisain.net
Can a trend reversal in CureVac N.V. lead to recoverySmart Swing Picks with Confirmed Signals - Newser
GSK set to get $500 million from settlement of mRNA lawsuit - The Economic Times
BioNTech (BNTX) Settles mRNA Patent Dispute with CureVac for US$370 Million - Yahoo Finance
BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal - BioPharma Dive
Drawdown in CureVac N.V. May Be Nearing EndFast Gaining Stock Screener Reports Released - beatles.ru
GSK Secures $370 Million In MRNA Patent Settlement Windfall - Finimize
CureVac Enters Agreements to Resolve mRNA Patent Litigation with Pfizer/BioNTech - Contract Pharma
CureVac announces resolution of patent litigation with Pfizer/BioNTech - Medical Dialogues
CureVac (CVAC) Secures $740M from Patent Settlement with Pfizer and BioNTech - GuruFocus
GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation - MarketScreener
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - Seeking Alpha
GSK to be paid up to £370 million after patent row settles in US - uk.finance.yahoo.com
GSK: $370m received as part of CureVac/BioNTech agreement - MarketScreener
mRNA rivals call truce as BioNTech prepares CureVac takeover - MarketScreener
GSK wins settlement, future royalties in CureVac mRNA patent dispute - MarketScreener
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement - Bloomberg.com
GSK Reaches $500M Agreement Over Covid-19 Jab Patent Row - AInvest
GSK To Get $370 Mln Upfront Payment From CureVac With MRNA Patent Settlement - Nasdaq
Will breakout in CureVac N.V. lead to full recoveryCommunity Picked Stocks with Trade Insights - Newser
Will CureVac N.V. stock benefit from AI tech trendsFast Gaining Stock Screener Reports Released - metal.it
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - Benzinga
How the U.S. mRNA Therapeutics Market Will Evolve by 2032 - openPR.com
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update - The Manila Times
Is CureVac N.V. a good long term investmentFree Investment Portfolio Suggestions - Jammu Links News
Bullish Candlestick Pattern Forms in CureVac N.V.AI Based High Gain Watchlist Scanner Shared - beatles.ru
What is CureVac N.V. company’s growth strategyMassive wealth growth - Jammu Links News
Should I hold or sell CureVac N.V. stock in 2025Superior portfolio returns - Jammu Links News
What makes CureVac N.V. stock price move sharplyHigh-return market picks - Jammu Links News
When is CureVac N.V. stock expected to show significant growthGet expert advice on portfolio optimization - Jammu Links News
CureVac N.V. Stock Analysis and ForecastMaximize gains with data-driven stock picks - Jammu Links News
How does CureVac N.V. generate profit in a changing economyFree Stock Market Trend Analysis - Jammu Links News
How volatile is CureVac N.V. stock compared to the marketStay ahead with daily market updates - Jammu Links News
Does CureVac N.V. stock perform well during market downturnsGet daily expert analysis for smarter investing - Jammu Links News
What are analysts’ price targets for CureVac N.V. in the next 12 monthsUnlock daily stock market insights for success - Jammu Links News
Is it the right time to buy CureVac N.V. stockSignificant capital appreciation - Jammu Links News
How strong is CureVac N.V. company’s balance sheetRetirement Planning Signals To Watch Now - jammulinksnews.com
Is CureVac N.V. stock overvalued or undervaluedReal Time Signals For Consistent Profits - Jammu Links News
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):